Roundtable: Overcoming Immunogenicity And Safety Assessment Challenges For Biologics And Biosimilars In Oncology

Biologics and biosimilars, such as ADCs and mAbs, hold great promise for treating even rare forms of cancer. However, testing for immunogenicity using these modalities presents a set of specific obstacles to overcome to ensure patient safety in clinical trials and beyond. Industry experts recently met to discuss effective strategies for moving forward.

Read the roundtable summary to explore:

Bridging immunogenicity assays from the pre-clinical to clinical setting and beyond
Balancing the complexities and benefits of multi-tier assays
Applying immunogenicity assays in new biologics and new biosimilars
Dealing with regulators: CDMO and developer experiences
Improving results with a flexible approach to neutralizing antibody assay selection
Looking ahead: The role of tech advances and AI

Download the Roundtable summary

Your Company Email Address

Opt In?

By completing this form You agree Citeline and Cerba Research may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and Cerba Research.